Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of increasing funding for (a) vaccines and (b) the wider medtech sector in the context of the US Government’s decision on mRNA vaccine research.

Vaccines are an important tool for preventing and lessening the impacts of disease. The Department invests in vaccine research through several routes, targeting interventions in areas essential for health resilience, such as mRNA vaccine technology. For instance, the Department funds research through the National Institute for Health and Care Research (NIHR), which includes the UK Vaccine Innovation Pathway to support the rapid set up and delivery of clinical trials in the United Kingdom, including the UK’s first norovirus mRNA vaccine trial. The Department also established the Official Development Assistance-funded UK Vaccine Network Project in 2015 and has funded the Coalition for Epidemic Preparedness Innovations since 2018.

More widely, the Government is partnering with industry to drive forward mRNA vaccine research and development. Through its ten-year strategic partnership with the Government, signed in 2022, Moderna will invest over £1 billion in mRNA research and development in the UK, strengthening the UK's vaccine manufacturing capacity through construction of the Moderna Innovation and Technology Centre. Additionally, the Government's strategic partnership with BioNTech will see 10,000 National Health Service patients provided with personalised cancer immunotherapies, including mRNA cancer vaccines, by 2030, ensuring that UK patients have early access to these innovative new treatments.

Supporting research into vaccines is critical to improving pandemic preparedness and delivering the global 100 Days Mission, which the UK has supported since its establishment. The mission aims to have safe and effective diagnostics, therapeutics, and vaccines available and equitably accessible in the first 100 days of a pandemic threat being identified. The £520 million Life Sciences Innovative Manufacturing Fund backs UK manufacturing and will bring globally mobile manufacturing investments, including vaccines and medical technology (MedTech), to the UK, strengthening the UK’s economy and generating high-skill, high-wage jobs.

The Government is also committed to supporting the MedTech industry, which is a central pillar in the UK’s life sciences sector and will help build an NHS that is fit for the future. The Government has recently set out its plans for life sciences in the 10-Year Health Plan and the Life Sciences Sector Plan, which includes enhancing support for MedTech small and medium-sized enterprises through UK Research and Innovation and NIHR.